Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- Section 1 Introduction
- Section 2 Research ethics
- Section 3 Translating addiction research
- 11 The public health implications of genetic research on addiction
- 12 Genetics, addiction, and stigma
- 13 Lay beliefs about genetic influences on the development of alcoholism: Implications for prevention
- 14 Personalizing risk: How behavior genetics research into addiction makes the political personal
- Section 4 Conclusions
- Index
- References
11 - The public health implications of genetic research on addiction
from Section 3 - Translating addiction research
Published online by Cambridge University Press: 05 September 2012
Edited by
Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- Section 1 Introduction
- Section 2 Research ethics
- Section 3 Translating addiction research
- 11 The public health implications of genetic research on addiction
- 12 Genetics, addiction, and stigma
- 13 Lay beliefs about genetic influences on the development of alcoholism: Implications for prevention
- 14 Personalizing risk: How behavior genetics research into addiction makes the political personal
- Section 4 Conclusions
- Index
- References
Summary
Introduction
Genetic research has identified a number of genetic variants that are believed to increase the risk of developing addictive disorders or predict responses to treatments for these disorders (see Chapter 2 of this volume for a review of the genetic research on alcohol dependence). This research has the potential to enhance public health through improved prevention and treatment of addiction. Predictive genetic screening might be used to identify persons at a greater risk of developing addiction and prevent them from doing so. Pharmacogenetic research may enable clinicians to better match persons with addictive disorders to more effective treatments, thereby minimizing side effects and relapse.
As well as having the potential to improve public health, research identifying genes predictive of addiction liability and treatment response may also be misused or misinterpreted in ways that harm individual and population health. It may negatively influence community attitudes to persons with a genetic predisposition to addiction, resulting in stigmatization of such individuals (Berghmans et al., 2009). Individuals may interpret genetic risk information in a deterministic way and believe they are powerless to change their behavior or their risk of addiction. Genetic risk information about addiction liability may also be used in a discriminatory way by employers or insurance companies (Taylor et al., 2008). Alcohol and tobacco industries may misuse this research to discourage population-level interventions aimed at reducing hazardous alcohol consumption and increasing smoking cessation (Gundle et al., 2010; Miller et al., 2012).
- Type
- Chapter
- Information
- Genetic Research on AddictionEthics, the Law, and Public Health, pp. 155 - 173Publisher: Cambridge University PressPrint publication year: 2012
References
2006 Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trialThe Journal of the American Medical Association 295 2003CrossRefGoogle ScholarPubMed
1997 Genetic susceptibility testing in smoking-cessation treatment: One-year outcomes of a randomized trialAddictive Behaviors 22 741CrossRefGoogle ScholarPubMed
2010 Vested interests, addiction research and public policyAddiction 105 4CrossRefGoogle ScholarPubMed
2004 http://news.bbc.co.uk/2/hi/health/4061137.stm
2010 Direct-to-consumer genotyping: are we ready for a brave new world?Clinical Chemistry 56 1056Google ScholarPubMed
2009 On the biomedicalization of alcoholismTheoretical Medical Bioethics 30 311CrossRefGoogle ScholarPubMed
2005 Lack of effect of D2 dopamine receptor taqI A polymorphism on smoking cessationNicotine & Tobacco Research 7 725CrossRefGoogle Scholar
2007 Catechol-O-Methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependenceBiological Psychiatry 61 111CrossRefGoogle ScholarPubMed
2009 Stigma and addiction: being and becomingAmerican Journal of Bioethics 9 18CrossRefGoogle ScholarPubMed
2009 The effectiveness of limiting alcohol outlet density as a means of reducing excessive alcohol consumption and alcohol-related harmsAmerican Journal of Preventative Medicine 37 556CrossRefGoogle ScholarPubMed
2005 News about genetics and smoking: Priming, family smoking history, and news story believability on inferences of genetic susceptibility to tobacco addictionCommunication Research 32 478CrossRefGoogle Scholar
2006 Potential for genetics to promote public health: Genetics research on smoking suggests caution about expectationsJournal of the American Medical Association 296 2480CrossRefGoogle ScholarPubMed
2011 Direct-to-consumer testing: if consumers are not anxious, why are policymakers?Human Genetics 130 23CrossRefGoogle Scholar
2010 The global research neglect of unassisted smoking cessation: causes and consequencesPLoS Medicine 7 e1000216CrossRefGoogle ScholarPubMed
2010 Understandings of basic genetics in the United States: results from a national survey of black and white men and womenPublic Health Genomics 13 467CrossRefGoogle ScholarPubMed
2009 Prediction and interaction in complex disease genetics: experience in type 1 diabetesPLoS Genetics 5 1000540CrossRefGoogle ScholarPubMed
2009 Substance use disorder genetic research: investigators and participants grapple with the ethical issuesPsychiatric Genetics 19 83CrossRefGoogle ScholarPubMed
2005 Neurobiology of addiction: Treatment and public policy ramificationsNature Neuroscience 8 1431CrossRefGoogle ScholarPubMed
2006 Interaction between variation in the D2 dopamine receptor () and the neuronal calcium sensor-1 () genes in predicting response to nicotine replacement therapy for tobacco dependencePharmacogenomics 6 194CrossRefGoogle ScholarPubMed
2007 The serotonin transporter polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trialNicotine & Tobacco Research 9 225CrossRefGoogle ScholarPubMed
2004 Ethics in population-based genetic researchAccountability Research 11 1CrossRefGoogle ScholarPubMed
2010 Alcohol policy reform in Australia: what can we learn from the evidence?Medical Journal of Australia 192 468Google ScholarPubMed
2009 www.egappreviews.org/
2010 The effectiveness of tax policy interventions for reducing excessive alcohol consumption and related harmsAmerican Journal of Preventative Medicine 38 217CrossRefGoogle ScholarPubMed
2008 A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implicationsDrug Metabolism Review 40 377CrossRefGoogle ScholarPubMed
2009 Multiple genetic tests for susceptibility to smoking do not outperform simple family historyAddiction 104 118CrossRefGoogle Scholar
2010 www.dnapolicy.org/resources/AlphabetizedDTCGeneticTesting Companies11.10.pdf
2004 www.genewatch.org/uploads/f03c6d66a9b354535738483c1c3d49e4/Nicotest_brief_final.pdf
2008 A risk allele for nicotine dependence in is a protective allele for cocaine dependenceBiological Psychiatry 64 922CrossRefGoogle ScholarPubMed
2010 To prove this is the industry’s best hope”: big tobacco’s support of research on the genetics of nicotine addictionAddiction 105 974CrossRefGoogle ScholarPubMed
2003 Genomic profiling to promote a healthy lifestyle: not ready for prime timeNature Genetics 34 347CrossRefGoogle ScholarPubMed
2005 British drinking: a suitable case for treatment?British Medical Journal 331 527CrossRefGoogle Scholar
2002 The genetics of tobacco use: methods, findings and policy implicationsTobacco Control 11 119CrossRefGoogle ScholarPubMed
2008 The genetics of nicotine addiction liability: ethical and social policy implicationsAddiction 103 350CrossRefGoogle ScholarPubMed
2008 Multiple ADH genes are associated with upper aerodigestive cancersNature Genetics 40 707CrossRefGoogle ScholarPubMed
2010 Evaluation of a brief web-based genetic feedback intervention for reducing alcohol-related health risks associated with Annals of Behavioral Medicine 40 77CrossRefGoogle ScholarPubMed
2005
2010 Myths, misconceptions and myopia: searching for clarity in the debate about the regulation of consumer geneticsPublic Health Genomics 13 322CrossRefGoogle ScholarPubMed
2009 Smokers’ beliefs about the inability to stop smokingAddictive Behavior 34 1005CrossRefGoogle ScholarPubMed
2008 Letting the genome out of the bottle – will we get our wish?New England Journal of Medicine 358 105CrossRefGoogle ScholarPubMed
2006 An intervention study of smoking cessation with feedback on genetic cancer susceptibility in JapanPreventive Medicine 42 102CrossRefGoogle ScholarPubMed
2006 Predictive testing for complex diseases using multiple genes: fact or fiction?Genetic Medicine 8 395CrossRefGoogle ScholarPubMed
2011 Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinkingAmerican Journal of Psychiatry 168 265CrossRefGoogle ScholarPubMed
2004 The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK populationAddiction Biology 9 221CrossRefGoogle Scholar
2003 Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and diseaseGenetics in Medicine 5 261CrossRefGoogle ScholarPubMed
2000 Challenges in communicating genetics: a public health approachGenetics in Medicine 2 198CrossRefGoogle ScholarPubMed
2004 An epidemiological assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventionsGenetics in Medicine 6 38CrossRefGoogle Scholar
2005 Pharmacogenetics-based therapeutic recommendations – ready for clinical practice?Nature Review of Drug Discovery 4 639CrossRefGoogle ScholarPubMed
2006 Application of aldehyde dehydrogenase 2 () genetic diagnosis in support of decreasing alcohol intakeJournal of Occupational Health 48 161CrossRefGoogle ScholarPubMed
2009 Findings on alcohol dependence point to promising avenues for targeted therapiesJournal of the American Medical Association 301 1643CrossRefGoogle ScholarPubMed
2006 Advancement of global health: key messages from the Disease Control Priorities ProjectLancet 367 1193CrossRefGoogle ScholarPubMed
2007 Monoamine oxidase, addiction, and the “warrior” gene hypothesisNew Zealand Medical Journal 120 2441Google ScholarPubMed
2010 Nicotine vaccines: will smokers take a shot at quitting?Nicotine Tobacco Research 12 390CrossRefGoogle Scholar
2006 Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatmentJournal of Psychopharmacology 20 7CrossRefGoogle ScholarPubMed
1997 Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking related cognitions, emotions and behavior changeHealth Psychology 16 87CrossRefGoogle ScholarPubMed
2003 Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trialHealth Psychology 22 541CrossRefGoogle Scholar
2004 The functional mu opioid receptor () variant predicts short-term response to nicotine replacement therapy in a clinical trialPharmacogenomics 4 184CrossRefGoogle Scholar
2006 Role of functional genetic variation in the dopamine D2 receptor () in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trialsNeuropsychopharmacology 31 231CrossRefGoogle ScholarPubMed
2004 Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for PsychopharmacologyJournal of Psychopharmacology 18 293CrossRefGoogle ScholarPubMed
1998 The new genetics. Psychological responses to genetic testingBritish Medical Journal 316 693CrossRefGoogle ScholarPubMed
2006 Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future researchSocial Science & Medicine 62 1360CrossRefGoogle ScholarPubMed
2010
2002 Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low incomeCancer Epidemiology, Biomarkers and Prevention 11 521Google ScholarPubMed
2010 Future health applications of genomics: priorities for communication, behavioral, and social sciences researchAmerican Journal of Preventive Medicine 38 556CrossRefGoogle ScholarPubMed
2008 An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commonsThe Journal of the American Medical Association 300 2669CrossRefGoogle ScholarPubMed
2006 Biomedicalization of Alcohol Studies: Methodological Shifts and Institutional ChallengesNew Brunswick, NJTransaction Publishers
2010 Effectiveness of policies maintaining or restricting days of alcohol sales on excessive alcohol consumption and related harmsAmerican Journal of Preventive Medicine 39 575CrossRefGoogle ScholarPubMed
2012 Addiction Neuroethics: The Ethics of Addiction Research and TreatmentNew YorkElsevierGoogle Scholar
2009 Australian study on public knowledge of human genetics and healthPublic Health Genomics 12 84CrossRefGoogle ScholarPubMed
2006 Lack of association of genotype with smoking cessation in a nicotine replacement therapy randomized trialCancer Epidemiology, Biomarkers and Prevention 15 398CrossRefGoogle Scholar
2007 Association of the mu-opioid receptor gene with smoking cessationPharmacogenomics Journal 7 353CrossRefGoogle ScholarPubMed
2009 Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicatorsAddiction Biology 14 328CrossRefGoogle ScholarPubMed
2003 A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patientsNeuropsychopharmacology 28 1546CrossRefGoogle ScholarPubMed
2001 Cancer epidemiology in the last century and the next decadeNature 411 390CrossRefGoogle ScholarPubMed
2007 Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled studyArchives of General Psychiatry 64 1069CrossRefGoogle ScholarPubMed
2009 A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkersExperimental and Clinical Psychopharmacology 17 122CrossRefGoogle ScholarPubMed
2001 The role of biological and genetic causal beliefs in the stigmatisation of mental patientsJournal of Mental Health 10 223Google Scholar
2008 Psychological and behavioural impact of genetic testing smokers for lung cancer risk: a phase II exploratory trialJournal of Health Psychology 13 481CrossRefGoogle ScholarPubMed
2000 Impact of genetic testing on causal models of heart disease and arthritis: an analogue studyPsychology & Health 14 1077CrossRefGoogle ScholarPubMed
2006 Can pharmacogenetics help rescue drugs withdrawn from the market?Pharmacogenomics 7 889CrossRefGoogle Scholar
2008 Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?Clinical Pharmacological Therapies 83 635CrossRefGoogle ScholarPubMed
2008 Primary care physicians’ willingness to offer a new genetic test to tailor smoking treatment, according to test characteristicsNicotine Tobacco Research 10 1037CrossRefGoogle Scholar
2001 The Structural Determinants of Youth Drug UseCanberraAustralian National Council on DrugsGoogle Scholar
2008 Investigating genetic discrimination in Australia: a large-scale survey of clinical genetics clientsClinical Genetics 74 20CrossRefGoogle ScholarPubMed
2008 www.abmrf.org
2000
2010 www.gao.gov/highlights/d10847thigh.pdf
2010 Birth of a brain disease: science, the state and addiction neuropoliticsHistory of the Human Sciences 23 52CrossRefGoogle ScholarPubMed
2009 Genetic variation in the gene affects mRNA levels and is associated with risk for alcohol dependenceMolecular Psychiatry 14 501CrossRefGoogle ScholarPubMed
2006 Combining psychosocial treatment with pharmacotherapy for alcohol dependenceJournal of Clinical Psychopharmacology 26 S37CrossRefGoogle ScholarPubMed
2008 Scientific responsibility for the dissemination and interpretation of genetic research: lessons from the “warrior gene” controversyJournal of Medical Ethics 34 507CrossRefGoogle ScholarPubMed
2002 Balancing life-style and genomics research for disease preventionScience 296 695CrossRefGoogle ScholarPubMed
2007 Prediction of individual genetic risk to disease from genome-wide association studiesGenome Research 17 1520CrossRefGoogle ScholarPubMed
2010 The genetic interpretation of area under the ROC curve in genomic profilingPLoS Genet 6 1000864CrossRefGoogle ScholarPubMed
2003 The impact of learning of a genetic predisposition to nicotine dependence: an analogue studyTobacco Control 12 227CrossRefGoogle Scholar
2010 Size of the direct-to-consumer genomic testing marketGenetic Medicine 12 594CrossRefGoogle ScholarPubMed